×
S&P 500   3,762.98 (-1.63%)
DOW   30,511.07 (-1.89%)
QQQ   279.49 (-0.94%)
AAPL   138.40 (-0.38%)
MSFT   256.31 (-1.26%)
META   161.58 (+0.97%)
GOOGL   2,175.65 (+0.04%)
AMZN   110.22 (+0.60%)
TSLA   663.10 (-2.74%)
NVDA   145.03 (-0.14%)
NIO   21.21 (-0.70%)
BABA   114.46 (-1.33%)
AMD   73.28 (-0.53%)
MU   54.43 (+1.45%)
CGC   2.66 (-5.34%)
T   20.83 (-2.25%)
GE   61.00 (-4.00%)
F   10.84 (-4.24%)
DIS   94.38 (-1.83%)
AMC   12.77 (-5.62%)
PFE   50.64 (-3.19%)
PYPL   71.76 (+0.50%)
NFLX   178.70 (-0.69%)
S&P 500   3,762.98 (-1.63%)
DOW   30,511.07 (-1.89%)
QQQ   279.49 (-0.94%)
AAPL   138.40 (-0.38%)
MSFT   256.31 (-1.26%)
META   161.58 (+0.97%)
GOOGL   2,175.65 (+0.04%)
AMZN   110.22 (+0.60%)
TSLA   663.10 (-2.74%)
NVDA   145.03 (-0.14%)
NIO   21.21 (-0.70%)
BABA   114.46 (-1.33%)
AMD   73.28 (-0.53%)
MU   54.43 (+1.45%)
CGC   2.66 (-5.34%)
T   20.83 (-2.25%)
GE   61.00 (-4.00%)
F   10.84 (-4.24%)
DIS   94.38 (-1.83%)
AMC   12.77 (-5.62%)
PFE   50.64 (-3.19%)
PYPL   71.76 (+0.50%)
NFLX   178.70 (-0.69%)
S&P 500   3,762.98 (-1.63%)
DOW   30,511.07 (-1.89%)
QQQ   279.49 (-0.94%)
AAPL   138.40 (-0.38%)
MSFT   256.31 (-1.26%)
META   161.58 (+0.97%)
GOOGL   2,175.65 (+0.04%)
AMZN   110.22 (+0.60%)
TSLA   663.10 (-2.74%)
NVDA   145.03 (-0.14%)
NIO   21.21 (-0.70%)
BABA   114.46 (-1.33%)
AMD   73.28 (-0.53%)
MU   54.43 (+1.45%)
CGC   2.66 (-5.34%)
T   20.83 (-2.25%)
GE   61.00 (-4.00%)
F   10.84 (-4.24%)
DIS   94.38 (-1.83%)
AMC   12.77 (-5.62%)
PFE   50.64 (-3.19%)
PYPL   71.76 (+0.50%)
NFLX   178.70 (-0.69%)
S&P 500   3,762.98 (-1.63%)
DOW   30,511.07 (-1.89%)
QQQ   279.49 (-0.94%)
AAPL   138.40 (-0.38%)
MSFT   256.31 (-1.26%)
META   161.58 (+0.97%)
GOOGL   2,175.65 (+0.04%)
AMZN   110.22 (+0.60%)
TSLA   663.10 (-2.74%)
NVDA   145.03 (-0.14%)
NIO   21.21 (-0.70%)
BABA   114.46 (-1.33%)
AMD   73.28 (-0.53%)
MU   54.43 (+1.45%)
CGC   2.66 (-5.34%)
T   20.83 (-2.25%)
GE   61.00 (-4.00%)
F   10.84 (-4.24%)
DIS   94.38 (-1.83%)
AMC   12.77 (-5.62%)
PFE   50.64 (-3.19%)
PYPL   71.76 (+0.50%)
NFLX   178.70 (-0.69%)
OTCMKTS:CELZ

Creative Medical Technology Stock Forecast, Price & News

$0.74
-0.01 (-1.33%)
(As of 07/1/2022 08:44 PM ET)
Add
Compare
Today's Range
$0.71
$0.83
50-Day Range
$0.62
$2.09
52-Week Range
$0.59
$20.00
Volume
2.83 million shs
Average Volume
1.19 million shs
Market Capitalization
$7.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Creative Medical Technology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,251.4% Upside
$10.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$39,750 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.66) to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.79 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive CELZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Creative Medical Technology and its competitors with MarketBeat's FREE daily newsletter.

Creative Medical Technology logo

About Creative Medical Technology (OTCMKTS:CELZ) Stock

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

CELZ Stock News Headlines

CANG,CELZ and BTTX among pre market gainers
Creative Medical Technology Holdings, Inc. (CELZ)
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CELZ
Fax
N/A
Employees
N/A
Year Founded
N/A

Company Calendar

Today
7/05/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+1,251.4%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$7.04 million
Optionable
Not Optionable
Beta
N/A














Creative Medical Technology Frequently Asked Questions

Should I buy or sell Creative Medical Technology stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Creative Medical Technology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Creative Medical Technology stock.
View analyst ratings for Creative Medical Technology
or view top-rated stocks.

What is Creative Medical Technology's stock price forecast for 2022?

1 Wall Street analysts have issued 1-year price objectives for Creative Medical Technology's shares. Their CELZ stock forecasts range from $10.00 to $10.00. On average, they expect Creative Medical Technology's share price to reach $10.00 in the next year. This suggests a possible upside of 1,251.4% from the stock's current price.
View analysts' price targets for Creative Medical Technology
or view top-rated stocks among Wall Street analysts.

How has Creative Medical Technology's stock price performed in 2022?

Creative Medical Technology's stock was trading at $2.21 at the start of the year. Since then, CELZ stock has decreased by 66.5% and is now trading at $0.74.
View the best growth stocks for 2022 here
.

Who are Creative Medical Technology's key executives?

Creative Medical Technology's management team includes the following people:
  • Mr. Timothy Warbington, Chairman, Pres & CEO (Age 60, Pay $98.68k)
  • Mr. Donald Dickerson, Sr. VP, CFO & Director (Age 57, Pay $87.5k)
  • Mr. Sahil Nock, Chief Commercial Officer

What other stocks do shareholders of Creative Medical Technology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Creative Medical Technology investors own include Co-Diagnostics (CODX), Actinium Pharmaceuticals (ATNM), FuelCell Energy (FCEL), iBio (IBIO), Infrax Systems (IFXY), Inovio Pharmaceuticals (INO), PharmaCyte Biotech (PMCB), Tonix Pharmaceuticals (TNXP), BioRestorative Therapies (BRTX) and Image Protect (IMTL).

What is Creative Medical Technology's stock symbol?

Creative Medical Technology trades on the OTCMKTS under the ticker symbol "CELZ."

How do I buy shares of Creative Medical Technology?

Shares of CELZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Creative Medical Technology's stock price today?

One share of CELZ stock can currently be purchased for approximately $0.74.

How much money does Creative Medical Technology make?

Creative Medical Technology (OTCMKTS:CELZ) has a market capitalization of $7.04 million.

How can I contact Creative Medical Technology?

Creative Medical Technology's mailing address is 2017 W Peoria Ave, PHOENIX, AZ 85029-4916, United States. The official website for Creative Medical Technology is www.creativemedicaltechnology.com. The company can be reached via phone at (602) 680-7439.

This page (OTCMKTS:CELZ) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.